We are committed to ensuring price doesn’t prevent our medicines getting to the people who need them.
Over the last several years, we’ve launched 13 groundbreaking medicines in areas of great need for innovation including multiple sclerosis, hemophilia, spinal muscular atrophy and different types of cancer and we’ve priced these medicines at or below (and in some cases significantly below) other available medicines approved by the U.S. Food and Drug Administration (FDA) to treat the same disease.
As an industry leader we are mindful of our responsibility to help drive meaningful change to lower patient out-of-pocket costs and save government programs money, while at the same time maintaining scientific innovation. We believe innovative payment models, combined with robust market competition mechanisms, are the most appropriate, effective and sustainable ways to reduce costs — and we have long advocated for such reforms.
We decided early on we did not want to follow the same pricing trends we’d been seeing. We wanted to make the best pricing decision we could for people living with multiple sclerosis and their families.
How We Priced our Breakthrough Medicine for Multiple Sclerosis
Living with a serious illness can come with many challenges - accessing the medicine you are prescribed shouldn't be one of them.
As a company with a long history of pursuing ground-breaking science to bring innovative medicines to patients, we strive to ensure that anyone who is prescribed one of our potentially life-changing medicines can get it - regardless of their ability to pay - and we offer several important support services to assist patients with access.
At every step of the way, from research to pricing, Genentech puts patients first. We strive for the right balance between ensuring people can access, afford and benefit from the medicines they need, while investing in future scientific breakthroughs and therapeutic advancements.
The revenue generated from our medicines allows us to invest more than $12 billion a year in research and development – more than any other health care company in the world. As a result, we have brought 19 innovative new medicines to patients over the last decade in areas such as cancer, neuroscience, respiratory and ophthalmology diseases, as well as devastating rare diseases like hemophilia and spinal muscular atrophy. Additionally, we continue to invest in significant and sustained research for each of our medicines even after they are approved.
Looking to the future, we remain committed to finding treatments for life-threatening and difficult-to-treat conditions such as other serious cancers, autoimmune conditions and Alzheimer’s disease as well as retinal disorders such as geographic atrophy and diabetic macular edema.